Dupilumab Plus Medium-Dose Inhaled Corticosteroid Improves Outcomes Compared with Placebo Plus High-Dose Inhaled Corticosteroid in Pediatric Patients with Uncontrolled Asthma
Monday, April 28, 2025
9:15am – 9:30am HST
Location: Convention Center: 327
Leonard B. Bacharier, Vanderbilt University Medical Center, Nashville, TN, United States; Jorge F. Maspero, Fundación CIDEA, Buenos Aires, Argentina, Buenos Aires, Buenos Aires, Argentina; Nikolaos G. Papadopoulos, NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS GREECE, Athens, Attiki, Greece; Theresa W.. Guilbert, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH, United States; Changming Xia, Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States; Mena Soliman, Regeneron, Tarrytown, NY, United States; Olivier Ledanois, SANOFI, Paris, Ile-de-France, France; Paul J. Rowe, Sanofi, Bridgewater, NJ, United States; Yamo Deniz, Regeneron, Tarrytown, NY, United States; Juby A. Jacob-Nara, Former Sanofi Employee, Bridgewater, NJ, NJ, United States; Harry Sacks, Regeneron Pharmaceuticals Inc,, Tarrytown, NY, United States
Presenting Author(s)
Changming Xia, PhD
Director Regeneron Pharmaceuticals Inc. Tarrytown, New York, United States
Disclosure(s):
Changming Xia, PhD: Regeneron Pharmaceuticals Inc. (Ongoing) (Products/Services: Employment with an ineligible company); Regeneron Pharmaceuticals Inc. − employees and shareholders (Ongoing) (Products/Services: Employment with an ineligible company, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds)
